IMACTIS to accelerate the development of its “GPS” dedicated to interventional radiology with €3m series B led by M Capital Partners

Grenoble – October 23rd, 2017 – IMACTIS is a medical technologies company founded by Lionel Carrat and Stéphane Lavallée. The company focuses on the development of innovative computer assisted solutions for interventional radiology. After successful launch of its solution in France and other European countries, a pool of investors is backing IMACTIS to accelerate its international go-to-market. The syndicate led by M Capital Partners includes BNP Paribas Développement, Crédit Agricole Alpes Développement, Crédit Agricole Création, Medevice and BizMedTech along with the founders and private shareholders.

IMACTIS develops and markets innovative solutions to assist interventional radiologists during minimally invasive needle procedures (biopsies, tumor ablations, vertebroplasties, infiltrations, drainages…). IMACTIS solution acts as a GPS for needle positioning. The objective is to increase accuracy and safety, facilitate complex procedures, reduce interventions duration, decrease the number of controls and improve patient treatment. IMACTIS is driving growth in interventional radiology, especially in the domain of interventional oncology.

With the help and support from interventional radiology experts and key opinion leaders, IMACTIS has developed a solution which ease-of-use is unique. There is strong IP in the technology and the company has unique patents. The system displays the anticipated trajectory of the needle in two reconstructed slices extracted from the CT volume, before its insertion. The system allows the radiologist to explore the patient’s anatomy and to plan the optimal trajectory to reach a target. Then, the system offers needle guidance and dynamic orientation control for better precision and faster execution, even for complex procedures. A first study with the Grenoble Hospital showed great clinical benefit with precision improved by a factor 2 compared to conventional methods.

The IMACTIS system can be connected to all types of CT scanners and is compatible with all types of needles. This will allow the company to build partnerships and meet all needs of both radiologists and industry players. The system is used in more than 20 centers in Europe (hospitals and cancer centers). More than 2,000 interventinos have been performed with the IMACTIS solution to date.

Lionel Carrat, CEO of IMACTIS stated “M Capital Partners is a prominent life science investor and was able to build a strong syndicate to fuel our growth. It is such a great support to have BNP Paribas Développement, Crédit Agricole Alpes Développement, Crédit Agricole Création, medtech expert Medevice and BizMedTech join us while our historical shareholders renew their trust in our ambitious growth plan. This will help a growing number of patients to benefit from our innovations, especially for tumor ablations with cryotherapy, radiofrequency or microwave needles which require precision in placement and reliable guiding solutions.”

“We are convinced that the founders track-record as well as Professor Ivan Bricault double qualification (interventional radiologist, Pr. Bricault also holds a PhD in applied mathematics) are a key success factor to address this high-growth market. Each year, more than 2 million procedures could be performed with the IMACTIS solution to improve efficacy of interventional radiology, a growing practice. IMACTIS is innovative and its patents portfolio is key to build partnerships with large industry players.” Says Yoann Bonnamour, senior business manager of M Capital Partners, Lyon.

“IMACTIS management team was successful in developing and selling an innovative solution, bringing added value to interventional radiologists. We believe this domain is going to grow and trust the team will show ability to continue growing in Europe and abroad”, says BNP Paribas Developpement.

Sabrina Kouidri is investment manager at Crédit Agricole Alpes Développement. She highlights “the team built trust with its historical investors and shareholder, delivering and executing what they promised. The future shows great potential for growth.”

Funds will mostly be used to continue growing sales in Europe, finalize FDA clearance and launch the solution in the United Stated as well as keep IMACTIS technological leadership. IMACTIS will benefit from its partnerships and references with some of the major players in the imaging or ablation needle industry in order to bundle the systems and accelerate market access.

See press release.

Press contact
Imactis, Lionel CARRAT
mail : info@imactis.com